The hypertension drug of Zydus Cadila and Intas Pharma has so far been approved for launch only in the US and Canada. Photo: HTNew Delhi: Two domestic drug makers are under the scanner of the pharmaceutical regulator for allegedly launching a combination drug to treat hypertension without mandatory prior approval. A drug maker needs approval from the Drug Controller General of India (DCGI) before launching any product. When the trials were still on, it was found that the combination drug is already available in the market. “Letters have been sent to the state drug controller and the companies to come clean on the issue.

Source: Mint November 09, 2017 21:56 UTC